

<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> ( Not for submission under 37 CFR 1.99)	Application Number		14608644	
	Filing Date		2015-01-29	
	First Named Inventor	Peter Wayne Marks		
	Art Unit	1627		
	Examiner Name	Jean-Louis Samira JM		
	Attorney Docket Number	PAT034678-US-CNT		

U.S.PATENTS							Remove	
Examiner Initial*	Cite No	Patent Number	Kind Code <sup>1</sup>	Issue Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear		
	1							
	2							
If you wish to add additional U.S. Patent citation information please click the Add button.							Add	
U.S.PATENT APPLICATION PUBLICATIONS							Remove	
Examiner Initial*	Cite No	Publication Number	Kind Code <sup>1</sup>	Publication Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear		
	1							
If you wish to add additional U.S. Published Application citation information please click the Add button.							Add	
FOREIGN PATENT DOCUMENTS							Remove	
Examiner Initial*	Cite No	Foreign Document Number <sup>3</sup>	Country Code <sup>2</sup> j	Kind Code <sup>4</sup>	Publication Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear	T <sup>5</sup>
	1	WO9409010	WO		1994-04-28	Sandoz-Erfindungen Verwaltungsgesellschaft MBH		<input type="checkbox"/>
	2	2022498	EP		2009-02-11	Novartis AG		<input type="checkbox"/>

<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> ( Not for submission under 37 CFR 1.99)	Application Number	14608644
	Filing Date	2015-01-29
	First Named Inventor	Peter Wayne Marks
	Art Unit	1627
	Examiner Name	Jean-Louis Samira JM
	Attorney Docket Number	PAT034678-US-CNT

If you wish to add additional Foreign Patent Document citation information please click the Add button <span style="float: right;">Add</span>			
NON-PATENT LITERATURE DOCUMENTS			Remove
Examiner Initials*	Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>5</sup>
	1	Hofsli et al., Molecular and Cellular Endocrinology, 2002, Vol.194, 165-173 " Expression of chromogranin A and somatostatin receptors in pancreatic AR42J cells"	<input type="checkbox"/>
	2	Dorland's illustrated Medical Dictionary,32nd Ed., p955, 2011	<input type="checkbox"/>
	3	Excerpt of the Merck Index for Everolimus P718, section 3950, Merck Index, 15th edition, 2013	<input type="checkbox"/>
	4	Hanin et al. "Effect of Interferon-a Treatment on Octreotide uptake in CA20948 tumors: A small animal PET study" The journal of Nuclear Medicine, 2011,52, N°4 pp580-585	<input type="checkbox"/>
	5	Öberg, "Guidelines for the Management of Gastroenteropancreatic Neuroendocrine Tumors (including Bronchopulmonary and Thymic Neoplasms)" Acta Oncologica, Vol 7, 2004	<input type="checkbox"/>
	6	Excerpt from Wikipedia "Response Evaluation Criteria in Solid Tumors" available at <a href="http://de.wikipedia.org/wiki/Response_Evaluation_Criteria_In_Solid_Tumors">http://de.wikipedia.org/wiki/Response_Evaluation_Criteria_In_Solid_Tumors</a> last accessed March 21, 2015	<input type="checkbox"/>
	7	Öberg, Kjell et al., "Guidelines for the Management of Gastroenteropancreatic Neuroendocrine Tumors (including Bronchopulmonary and Thymic Neoplasms) Part II" Acta Oncologica, Vol 43, 2004	<input type="checkbox"/>
	8	Tabernero et al., " A phase Study with Tumor molecular pharmacodynamics (MPD) evaluation of dose and schedule of the oral mTOR-inhibitor Everolimus (RAD001) in patients (pts) with advanced solid tumors" Journal of Clinical Oncology Vol.23, 2005	<input type="checkbox"/>
	9	Vignot et al., "mTOR targeted therapy of cancer with rapamycin derivatives" Annals of Oncology, Vol.16, 22 Feb 2005 pp525-537	<input type="checkbox"/>

<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> ( Not for submission under 37 CFR 1.99)	Application Number	14608644
	Filing Date	2015-01-29
	First Named Inventor	Peter Wayne Marks
	Art Unit	1627
	Examiner Name	Jean-Louis Samira JM
	Attorney Docket Number	PAT034678-US-CNT

10	Suzuki et al.: "Monitoring of response to radiation therapy for human tumor xenografts using 99mTc-HL91 (4,9-diaza-3,3,10,10-tetramethyldodecan-2,11-dione dioxime)" Annals of Nuclear Medicine, Vol.17 (2) , 2003	<input type="checkbox"/>
11	Excerpt from the ATCC catalogue (HCT116) <a href="http://www.lgestandards-atcc.org/Products/All/CCL-247.aspx">http://www.lgestandards-atcc.org/Products/All/CCL-247.aspx</a> last accessed March 31, 2015	<input type="checkbox"/>
12	Excerpt from the ATCC catalogue (A549) <a href="http://www.lgestandards-atcc.org/Products/All/CCL-185.aspx.geo_country-de">http://www.lgestandards-atcc.org/Products/All/CCL-185.aspx.geo_country-de</a> last accessed March 31, 2015	<input type="checkbox"/>
13	Excerpt from the database clinical trials.gov Efficacy and Safety of Everolimus (RAD001) Compared to Placebo in Patients V Neuroendocrine Tumors (Radiant-3) January 4, 2015	<input type="checkbox"/>
14	Dancey, Janet et al., "Issues and progress with Protein Kinase inhibitors for Cancer Treatment" Nature: Reviews Drug Discovery, Vol.2, 2003	<input type="checkbox"/>
15	Yao et al., "Phase II Study of RAD001 (everolimus) and depot octreotide (Sandostatin LAR) in patients with advanced low grade neuroendocrine carcinoma (LGNET) Journal of Clinical Oncology, Vol.24, No18S, 2006	<input type="checkbox"/>
16	Excerpt of the Merck Index for Everolimus, section 3907, Merck Index, 14th edition, 2005	<input type="checkbox"/>
17	Yao, James C. et al., "Everolimus for advanced pancreatic neuroendocrine tumors" The New England Journal of Medicine, Vol.364, 2011 pp514-523	<input type="checkbox"/>
18	Öberg, K "Treatment of Neuroendocrine Tumours of the Gastrointestinal tract" Oncologia, Vol.27, No4, 2004 pp185-189	<input type="checkbox"/>
19	Rosewicz et al., "An Amphicrine pancreatic cell line :AR42J cells combine exocrine and neuroendocrine properties" European Journal of Cell Biology vol.59, pp80-91, 1992	<input type="checkbox"/>
20	Ohnishi et al., "Conversion of Amylase-secreting Rat pancreatic AR42J Cells to Neuronlike Cells by Activin A" Journal of Clinical Investigation, The American Society for Clinical Investigations, Vol.95, May 1995 pp2304-2314	<input type="checkbox"/>

<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT ( Not for submission under 37 CFR 1.99)</b>	Application Number	14608644
	Filing Date	2015-01-29
	First Named Inventor	Peter Wayne Marks
	Art Unit	1627
	Examiner Name	Jean-Louis Samira JM
	Attorney Docket Number	PAT034678-US-CNT

21	Von Wichert et al., "Insulin-like Growth Factor-I is an Autocrine Regulator of Chromogranin A Secretion and Growth in Human Neuroendocrine Tumor Cells", Cancer Research, Vol.60, pp4573-4581 15 Aug 2000	<input type="checkbox"/>
22	Evers et al., "The Human Carcinoid Cell Line , BON a Model System for the Study of Carcinoid Tumors", Annals of New York Academy Sciences, Vol.733, pp393-406, 1992	<input type="checkbox"/>
23	Dutcher Janice P., "Mammalian Target of Rapamycin Inhibition", Clinical Cancer Research, Vol.10, pp6382s-6387s, 2004	<input type="checkbox"/>
24	Crewe et al, "Regulation of Cell Growth and Cyclin D1 Expression by the Constitutively Active FRAP-p70s6k Pathway in Human Pancreatic Cancer Cells", Cancer Research, Vol.59, pp3581-3587, 1 August 1999	<input type="checkbox"/>
25	Shah et al., " FRAP-p70s6k Signaling is Required for Pancreatic Cancer Cell Proliferation", Journal of Surgical Research, Vol.97, pp123-130, 2001	<input type="checkbox"/>
26	Novartis Press Release on Pivotal Phase III trial of Novartis drug Afinitor®, June 2010	<input type="checkbox"/>
27	Guidance for Industry _ Information Program on Clinical Trials for Serious Diseases and Conditions US Dpt of Health and Human Services FDA March 2002	<input type="checkbox"/>
28	- M. A. Kouvaraki: "Fluorouracil, Doxorubicin, and Streptozocin in the Treatment of Patients With Locally Advanced and Metastatic Pancreatic Endocrine Carcinomas", Journal of Clinical Oncology, vol. 22, no. 23, 13 October 2004 (2004-10-13), pages 4762-4771, XP055093883, ISSN: 0732-183X, DOI: 10.1200/JCO.2004.04.024	<input type="checkbox"/>

If you wish to add additional non-patent literature document citation information please click the Add button **Add**

**EXAMINER SIGNATURE**

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> See Kind Codes of USPTO Patent Documents at [www.USPTO.GOV](http://www.USPTO.GOV) or MPEP 901.04. <sup>2</sup> Enter office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>3</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>4</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>5</sup> Applicant is to place a check mark here if English language translation is attached.

<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> ( Not for submission under 37 CFR 1.99)	Application Number	14608644
	Filing Date	2015-01-29
	First Named Inventor	Peter Wayne Marks
	Art Unit	1627
	Examiner Name	Jean-Louis Samira JM
	Attorney Docket Number	PAT034678-US-CNT

**CERTIFICATION STATEMENT**

Please see 37 CFR 1.97 and 1.98 to make the appropriate selection(s):

That each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement. See 37 CFR 1.97(e)(1).

**OR**

That no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquiry, no item of information contained in the information disclosure statement was known to any individual designated in 37 CFR 1.56(c) more than three months prior to the filing of the information disclosure statement. See 37 CFR 1.97(e)(2).

- See attached certification statement.
- The fee set forth in 37 CFR 1.17 (p) has been submitted herewith.
- A certification statement is not submitted herewith.

**SIGNATURE**

A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the form of the signature.

Signature	/Gregory Ferraro/	Date (YYYY-MM-DD)	2015-04-01
Name/Print	Gregory Ferraro	Registration Number	36134

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 1 hour to complete, including gathering, preparing and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. **DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

# Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

## Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

## Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

## Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

## API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

## LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

## FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

## E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.